MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing
- Journal:
- PLOS Biology
- Published:
- Affiliations:
- 1
- Authors:
- 24
| Institutions | Authors | Share |
|---|---|---|
| Merck - Rahway, United States of America (USA) | 1.00 |